Published in Clin Cancer Res on January 03, 2013
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood (2014) 2.44
Predicting response to epigenetic therapy. J Clin Invest (2014) 1.16
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol (2016) 0.98
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia (2013) 0.93
The myelodysplastic syndrome as a prototypical epigenetic disease. Blood (2013) 0.90
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest (2015) 0.90
Gender, cytidine deaminase, and 5-aza/decitabine--letter. Clin Cancer Res (2013) 0.88
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer (2013) 0.82
Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett (2015) 0.81
Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica (2014) 0.79
An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. Oncotarget (2015) 0.79
The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia (2014) 0.79
Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome. Oncotarget (2015) 0.77
Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. Cancer Epidemiol (2015) 0.77
Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet (2015) 0.76
SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res (2014) 0.76
Gender, cytidine deaminase, and 5-aza/decitabine--response. Clin Cancer Res (2013) 0.76
Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol (2014) 0.75
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med (2016) 0.75
Spotlight on decitabine for myelodysplastic syndromes in Chinese patients. Onco Targets Ther (2015) 0.75
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leuk Lymphoma (2016) 0.75
Enhanced in Vitro Anti-Tumor Activity of 5-Azacytidine by Entrapment into Solid Lipid Nanoparticles. Adv Pharm Bull (2016) 0.75
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clin Pharmacokinet (2017) 0.75
5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. Pharmaceuticals (Basel) (2017) 0.75
Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell Reports (2017) 0.75
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell (1983) 3.56
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol (1965) 2.92
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res (2007) 2.04
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol (2009) 2.02
Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol (1971) 1.97
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood (2008) 1.71
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol (2009) 1.69
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res (2010) 1.37
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom (2006) 1.30
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res (2006) 1.30
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia (2011) 1.25
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol (2005) 1.15
Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn (2006) 1.15
Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol (2009) 1.11
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res (1986) 1.11
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia (2011) 1.09
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res (2004) 1.07
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Cancer Res (1970) 1.03
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood (2011) 1.02
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol (1995) 1.02
Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (2008) 0.97
Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol (1998) 0.96
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics (2007) 0.96
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol (2008) 0.94
Retracted A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia (2007) 0.93
Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep (1979) 0.93
Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol (2012) 0.91
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget (2012) 0.89
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol (2004) 0.89
Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer Chemother Rep (1976) 0.89
Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood (1987) 0.88
Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. BMC Bioinformatics (2009) 0.87
Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Bone Marrow Res (2011) 0.86
Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep (2004) 0.86
Determination of plasma cytidine deaminase activity by HPLC. Biomed Chromatogr (1987) 0.85
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. Leukemia (1991) 0.85
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol (2005) 0.84
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol (1999) 0.82
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol (2010) 0.81
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemother Pharmacol (1992) 0.80
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 6.47
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood (2007) 3.89
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res (2006) 3.72
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res (2008) 3.51
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood (2008) 2.87
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood (2012) 2.55
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood (2012) 2.50
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res (2013) 2.24
The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer (2007) 2.21
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol (2009) 2.03
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood (2012) 1.98
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res (2004) 1.91
Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood (2004) 1.83
EVI1 induces myelodysplastic syndrome in mice. J Clin Invest (2004) 1.72
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol (2009) 1.68
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc (2010) 1.63
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol (2012) 1.61
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res (2013) 1.60
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood (2011) 1.59
Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sci U S A (2006) 1.59
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma (2008) 1.53
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res (2013) 1.51
Retinal pigment epithelium lipofuscin proteomics. Mol Cell Proteomics (2008) 1.50
Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2004) 1.46
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
Non-destructive clinical assessment of occlusal caries lesions using near-IR imaging methods. Lasers Surg Med (2011) 1.43
Comparative phloem chemistry of Manchurian (Fraxinus mandshurica) and two North American ash species (Fraxinus americana and Fraxinus pennsylvanica). J Chem Ecol (2007) 1.42
Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania. Leuk Lymphoma (2011) 1.42
Optic disc area and correlation with central corneal thickness, corneal hysteresis and ocular pulse amplitude in glaucoma patients and controls. Clin Experiment Ophthalmol (2010) 1.42
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma (2014) 1.41
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol (2012) 1.40
Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics (2009) 1.39
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol (2009) 1.39
Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood (2013) 1.34
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood (2012) 1.33
Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. Invest Ophthalmol Vis Sci (2006) 1.32
SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood (2011) 1.27
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res (2010) 1.26
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med (2002) 1.25
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell (2011) 1.24
Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res (2003) 1.24
Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet (2012) 1.24
12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys (2005) 1.23
Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics (2010) 1.22
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc (2005) 1.22
Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol (2007) 1.22
Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol (2006) 1.21
Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem (2014) 1.19
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res (2009) 1.16
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost (2005) 1.16
Normal and transforming functions of RUNX1: a perspective. J Cell Physiol (2006) 1.15
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica (2012) 1.13
Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A (2008) 1.12
The Rose-comb mutation in chickens constitutes a structural rearrangement causing both altered comb morphology and defective sperm motility. PLoS Genet (2012) 1.12
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One (2012) 1.11
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol (2013) 1.10
Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials. J Clin Oncol (2013) 1.10
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood (2013) 1.10
Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol (2011) 1.09
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood (2010) 1.09
Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics (2009) 1.08
Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers. Radiat Res (2011) 1.07
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica (2011) 1.07
Perforin gene mutations in patients with acquired aplastic anemia. Blood (2007) 1.07
Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol (2007) 1.05
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol (2010) 1.05
Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther (2010) 1.05